Methyl 2-({[(4Z)-5-oxo-3-phenyl-4,5-dihydro-1,2-oxazol-4-ylidene]methyl}amino)acetate

Catalog No. :
ACTSXQ965
CAS No. :
477851-05-1
Molecular Formula :
C13H12N2O4
Molecular Weight :
260.25

IUPAC Name:methyl (Z)-((5-oxo-3-phenylisoxazol-4(5H)-ylidene)methyl)glycinate

Methyl 2-({[(4Z)-5-oxo-3-phenyl-4,5-dihydro-1,2-oxazol-4-ylidene]methyl}amino)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$327.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 2-({[(4Z)-5-oxo-3-phenyl-4,5-dihydro-1,2-oxazol-4-ylidene]methyl}amino)acetate
IUPAC Namemethyl (Z)-((5-oxo-3-phenylisoxazol-4(5H)-ylidene)methyl)glycinate
MDL No.MFCD00138284
Molecular FormulaC13H12N2O4
Molecular Weight260.25
SMILESCOC(=O)CN/C=C1\C(=O)ON=C1C1=CC=CC=C1
InChI KeyQWJKPONUAZJXFU-YFHOEESVSA-N
SynonymMETHYL 2-(([5-OXO-3-PHENYL-4(5H)-ISOXAZOLYLIDEN]METHYL)AMINO)ACETATE;methyl 2-({[(4Z)-5-oxo-3-phenyl-4,5-dihydro-1,2-oxazol-4-ylidene]methyl}amino)acetate;Glycine, N-[(5-oxo-3-phenyl-4(5H)-isoxazolylidene)methyl]-, methyl ester
CAS No.477851-05-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACTSXQ965 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTSXQ965 route product structure diagram
    ACTSXQ965477851-05-1
Inquiry

2. ACTSXQ965 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTSXQ965 route product structure diagram
    ACTSXQ965477851-05-1
Inquiry

Comments (0)